Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

ASCO

Home/Tag:ASCO
12 08, 2015

BREAKING NEWS: MMRF helps push expanded access for dararumumab

Tags: , , , |2 Comments

Today is your last chance to participate in a focus group study using your smart phones. Amazon gift cards will be given to all who participate. Contact Kristin Mraz,Community Recruitment Manager - WEGO Health, 177 Tremont Street, 3rd Floor,Boston, MA,02111 - cell:  518.774.6114 - office:  617.863.7745 - fax:  617.426.5027 - kristinm@wegohealth.com. I've worked with these

9 06, 2015

Dr. Rajkumar shares list of most important ASCO trials

Tags: , , , |7 Comments

Renowned Tweeter, Cindy from New Jersey, @Myeloma Teacher, passed along Dr. Vincent Rajkumar's Top Seven myeloma-related abstracts from this year's American Society of Clinical Oncology annual meetings in Chicago: Top 7 #ASCO15 #Myeloma Abstracts - @VincentRK 7- Panorama - http://abstracts.asco.org/156/AbstView_156_146520.h tml 6- Elo- Vd vs Vd - http://abstracts.asco.org/156/AbstView_156_144027.h tml 5- CHAMPION - http://abstracts.asco.org/156/AbstView_156_147850.html 4-CALGB Len

4 06, 2015

ASCO NEWS: ARRY-520 (filanesib) missing in action?

Tags: , , |2 Comments

Reports about the promising and innovative new myeloma therapy, ARRY-520 (filanesib), were conspicuously absent at this year's American Society of Clinical Oncology (ASCO) meetings this year in Chicago. Many myeloma specialists are hopeful that filanesib will match or even exceed the headline making results revealed for  daratumumab at this year's annual event.  Yet the only

3 06, 2015

ASCO News: 11;14 translocation data and elotuzumab results underwhelming

Tags: , , , , |2 Comments

I'm still hoping for some significant myeloma related data to emerge as the American Society of Clinical Oncology (ASCO) meetings wide down in Chicago.  In the meantime, the Myeloma Beacon did a nice job reviewing several poster studies which focused on my genetic abnormality: an 11;14 translocation I developed after my first stem cell transplant.

2 06, 2015

Groundbreaking immunotherapy drugs won’t be cheap, warns ranking ASCO oncologist

Tags: , , , |5 Comments

As expected, general oncology news is overwhelming myeloma updates at this year's American Society of Clinical Oncology (ASCO) meetings in Chicago.  Emerging themes are dominated by success among several immunotherapies and biologics used to battle advanced melanoma (skin cancer), a number of other solid tumor cancer types and soft tissue sarcomas.  The overriding mainstream media

12 06, 2014

SAR650984: Immunotherapy drug exceeds expectations

Tags: , , , , , |2 Comments

I have written a lot about SAR650984 recently.  SAR is an anti-CD38 monoclonal antibody.  Myeloma specialist, Dr. Thomas Martin, calls it "Along with daratumumab, the next blockbuster drug for myeloma. Here's an introduction to a helpful, five minute video produced by our friends at Patient Power during ASCO: Myeloma Research Progress: Anti-CD38 Monoclonal Antibodies in

9 06, 2014

Pat’s 2014 ASCO Review

Tags: , , , |7 Comments

Disappointed with limited of myeloma related news trickling out of Chicago last week?  You shouldn't be. True, there wasn't a lot of new data presented at this year's American Society of Clinical Oncology (ASCO) meetings.  But some was significant.  And more will be available June 12th - 15th at the European Hematology Association (EHA) conference

2 06, 2014

When practical trumps theoretical

Tags: , , |5 Comments

Today is myeloma day at the American Society of Clinical Oncology annual meetings in Chicago.  There isn't a lot of myeloma related data being presented this year, but the important stuff is out today.  Normally I'd be there covering the event.  Not this year.  I spent today at Mayo Clinic in Jacksonville, Florida. Just finishing

1 06, 2014

All relapsed/refractory patients not created equal

Tags: , , , |5 Comments

As I mentioned earlier this week, there isn't much myeloma related activity at the American Society of Clinical Oncology (ASCO) until Monday.  That gives us a chance to review a couple of important things to look for when comparing one experimental therapy to another. Let's start with relapsed/refractory.  Someone who relapses isn't necessarily refractory (resistant)

31 05, 2014

MMRF excited about new myeloma therapy, SAR650984

Tags: , , , , |8 Comments

Walter Capone, President of the Multiple Myeloma Research Foundation (MMRF), is excited about a new myeloma therapy: SAR650984.  He mentioned this exciting new therapeutic option for heavily pretreated multiple myeloma patients while we were working together in Tampa two weeks ago. Here's the MMRF's press release announcing Dr. Thomas Martin's presentation about SAR650984 at ASCO

4 06, 2013

Evidence starting to mount that maintenance therapy may help us live longer

Tags: , , , , , |0 Comments

Incremental baby steps.  I hope I haven't given the wrong impression about myeloma news coming out of Chicago at this year's American Society of Clinical Oncology (ASCO) meetings.  I've been whining about how there hadn't been any big myeloma related news.  That part is true.  But there are hundreds of clinical trial results being presented